The Lancet study was a randomized trial with > 200 patients that showed no clinical benefits of remdesivir but did reveal some adverse effects. That's worrying.

The Lancet study was a randomized trial with > 200 patients that showed no clinical benefits of remdesivir but did reveal some adverse effects. That's worrying. It's not the game changer that azidothymidine was for AIDS/HIV. The issue with remdesivir in mild cases is that it's expensive to produce (six steps, two at low temperature, outside the capability of many contract shops) and that multigram amounts are required for a course of treatment. It's not what you want to have for that group.